Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 971 entries
Sorted by: Best Match Show Resources per page
Image guided surgery in the management of head and neck cancer.

Oral oncology

Iqbal H, Pan Q.
PMID: 27208842
Oral Oncol. 2016 Jun;57:32-9. doi: 10.1016/j.oraloncology.2016.04.007. Epub 2016 Apr 25.

Complete resection of head and neck tumors relies on palpation and visual inspection. Achieving a negative margin in remote locations in the head and neck region, especially in close proximity to critical structures, is often difficult to achieve. Positive...

Cite
Iqbal H, Pan Q. Image guided surgery in the management of head and neck cancer. Oral Oncol. 2016;57:32-9doi: 10.1016/j.oraloncology.2016.04.007.
Iqbal, H., & Pan, Q. (2016). Image guided surgery in the management of head and neck cancer. Oral oncology, 5732-9. https://doi.org/10.1016/j.oraloncology.2016.04.007
Iqbal, Hassan, and Pan, Quintin. "Image guided surgery in the management of head and neck cancer." Oral oncology vol. 57 (2016): 32-9. doi: https://doi.org/10.1016/j.oraloncology.2016.04.007
Iqbal H, Pan Q. Image guided surgery in the management of head and neck cancer. Oral Oncol. 2016 Jun;57:32-9. doi: 10.1016/j.oraloncology.2016.04.007. Epub 2016 Apr 25. PMID: 27208842.
Copy Download .nbib Format: NLM
"P53 tumor suppressor gene as a clonal marker in head and neck squamous cell carcinoma: P53 mutations in primary tumor and matched lymph node metastases" by G.W.A. Tjebbes Et al. Oral oncology 35, pp 384-389.

Oral oncology

[No authors listed]
PMID: 10899681
Oral Oncol. 2000 Jul;36(4):395. doi: 10.1016/s1368-8375(00)00018-x.

No abstract available.

Cite
"P53 tumor suppressor gene as a clonal marker in head and neck squamous cell carcinoma: P53 mutations in primary tumor and matched lymph node metastases" by G.W.A. Tjebbes Et al. Oral oncology 35, pp 384-389. Oral Oncol. 2000;36(4):395doi: 10.1016/s1368-8375(00)00018-x.
(2000). "P53 tumor suppressor gene as a clonal marker in head and neck squamous cell carcinoma: P53 mutations in primary tumor and matched lymph node metastases" by G.W.A. Tjebbes Et al. Oral oncology 35, pp 384-389. Oral oncology, 36(4), 395. https://doi.org/10.1016/s1368-8375(00)00018-x
""P53 tumor suppressor gene as a clonal marker in head and neck squamous cell carcinoma: P53 mutations in primary tumor and matched lymph node metastases" by G.W.A. Tjebbes Et al. Oral oncology 35, pp 384-389." Oral oncology vol. 36,4 (2000): 395. doi: https://doi.org/10.1016/s1368-8375(00)00018-x
"P53 tumor suppressor gene as a clonal marker in head and neck squamous cell carcinoma: P53 mutations in primary tumor and matched lymph node metastases" by G.W.A. Tjebbes Et al. Oral oncology 35, pp 384-389. Oral Oncol. 2000 Jul;36(4):395. doi: 10.1016/s1368-8375(00)00018-x. PMID: 10899681.
Copy Download .nbib Format: NLM
Editorial.

Oral oncology

Scully C.
PMID: 14662407
Oral Oncol. 2004 Jan;40(1):1. doi: 10.1016/j.oraloncology.2003.09.007.

No abstract available.

Cite
Scully C. Editorial. Oral Oncol. 2004;40(1):1doi: 10.1016/j.oraloncology.2003.09.007.
Scully, C. (2004). Editorial. Oral oncology, 40(1), 1. https://doi.org/10.1016/j.oraloncology.2003.09.007
Scully, Crispian. "Editorial." Oral oncology vol. 40,1 (2004): 1. doi: https://doi.org/10.1016/j.oraloncology.2003.09.007
Scully C. Editorial. Oral Oncol. 2004 Jan;40(1):1. doi: 10.1016/j.oraloncology.2003.09.007. PMID: 14662407.
Copy Download .nbib Format: NLM
Retraction notice to 'When is an oral leukoplakia premalignant?' [Oral Oncol. 38 (2002) 813-814].

Oral oncology

[No authors listed]
PMID: 17457992
Oral Oncol. 2007 Apr;43(4):419. doi: 10.1016/j.oraloncology.2007.01.002.

No abstract available.

Cite
Retraction notice to 'When is an oral leukoplakia premalignant?' [Oral Oncol. 38 (2002) 813-814]. Oral Oncol. 2007;43(4):419doi: 10.1016/j.oraloncology.2007.01.002.
(2007). Retraction notice to 'When is an oral leukoplakia premalignant?' [Oral Oncol. 38 (2002) 813-814]. Oral oncology, 43(4), 419. https://doi.org/10.1016/j.oraloncology.2007.01.002
"Retraction notice to 'When is an oral leukoplakia premalignant?' [Oral Oncol. 38 (2002) 813-814]." Oral oncology vol. 43,4 (2007): 419. doi: https://doi.org/10.1016/j.oraloncology.2007.01.002
Retraction notice to 'When is an oral leukoplakia premalignant?' [Oral Oncol. 38 (2002) 813-814]. Oral Oncol. 2007 Apr;43(4):419. doi: 10.1016/j.oraloncology.2007.01.002. PMID: 17457992.
Copy Download .nbib Format: NLM
A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ).

Oral oncology

Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, Di Lenarda R, Biasotto M.
PMID: 25240948
Oral Oncol. 2014 Nov;50(11):1049-57. doi: 10.1016/j.oraloncology.2014.08.016. Epub 2014 Sep 17.

OBJECTIVES: The clinical management of bisphosphonate-related osteonecrosis of the jaw (BRONJ) remains controversial. Since universally accepted guidelines have not been released yet, clinicians usually chose the type of treatment according to position papers based on expert opinion, or on...

Cite
Rupel K, Ottaviani G, Gobbo M, et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014;50(11):1049-57doi: 10.1016/j.oraloncology.2014.08.016.
Rupel, K., Ottaviani, G., Gobbo, M., Contardo, L., Tirelli, G., Vescovi, P., Di Lenarda, R., & Biasotto, M. (2014). A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral oncology, 50(11), 1049-57. https://doi.org/10.1016/j.oraloncology.2014.08.016
Rupel, Katia, et al. "A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ)." Oral oncology vol. 50,11 (2014): 1049-57. doi: https://doi.org/10.1016/j.oraloncology.2014.08.016
Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, Di Lenarda R, Biasotto M. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol. 2014 Nov;50(11):1049-57. doi: 10.1016/j.oraloncology.2014.08.016. Epub 2014 Sep 17. PMID: 25240948.
Copy Download .nbib Format: NLM
Intraoral confocal microscopy of suspicious oral lesions: a prospective case series.

International journal of dermatology

Contaldo M, Lauritano D, Carinci F, Romano A, Di Stasio D, Lajolo C, Della Vella F, Serpico R, Lucchese A.
PMID: 31287162
Int J Dermatol. 2019 Jul 09; doi: 10.1111/ijd.14574. Epub 2019 Jul 09.

BACKGROUND: Oral squamous cell carcinoma (OSCC) accounts for more than 90% of oral epithelial malignancies and often arises from precursor lesions, whose diagnosis is based on biopsy and histopathology. In vivo reflectance confocal microscopy (RCM) images the vital tissues...

Cite
Contaldo M, Lauritano D, Carinci F, et al. Intraoral confocal microscopy of suspicious oral lesions: a prospective case series. Int J Dermatol. 2019;doi: 10.1111/ijd.14574.
Contaldo, M., Lauritano, D., Carinci, F., Romano, A., Di Stasio, D., Lajolo, C., Della Vella, F., Serpico, R., & Lucchese, A. (2019). Intraoral confocal microscopy of suspicious oral lesions: a prospective case series. International journal of dermatology, . https://doi.org/10.1111/ijd.14574
Contaldo, Maria, et al. "Intraoral confocal microscopy of suspicious oral lesions: a prospective case series." International journal of dermatology vol. (2019). doi: https://doi.org/10.1111/ijd.14574
Contaldo M, Lauritano D, Carinci F, Romano A, Di Stasio D, Lajolo C, Della Vella F, Serpico R, Lucchese A. Intraoral confocal microscopy of suspicious oral lesions: a prospective case series. Int J Dermatol. 2019 Jul 09; doi: 10.1111/ijd.14574. Epub 2019 Jul 09. PMID: 31287162.
Copy Download .nbib Format: NLM
Reconstruction Special Edition, Issue 1.

Oral oncology

Old M.
PMID: 29103746
Oral Oncol. 2017 Nov;74:157-158. doi: 10.1016/j.oraloncology.2017.10.015.

No abstract available.

Cite
Old M. Reconstruction Special Edition, Issue 1. Oral Oncol. 2017;74:157-158doi: 10.1016/j.oraloncology.2017.10.015.
Old, M. (2017). Reconstruction Special Edition, Issue 1. Oral oncology, 74157-158. https://doi.org/10.1016/j.oraloncology.2017.10.015
Old, Matthew. "Reconstruction Special Edition, Issue 1." Oral oncology vol. 74 (2017): 157-158. doi: https://doi.org/10.1016/j.oraloncology.2017.10.015
Old M. Reconstruction Special Edition, Issue 1. Oral Oncol. 2017 Nov;74:157-158. doi: 10.1016/j.oraloncology.2017.10.015. PMID: 29103746.
Copy Download .nbib Format: NLM
The learning experience of basic science and clinical dentistry by postgraduate students in Institute of Clinical Dentistry and Institute of Oral Biology.

Journal of dental sciences

Yang H, Chen HY, Lin HY, Chen HM.
PMID: 31528255
J Dent Sci. 2019 Sep;14(3):277-280. doi: 10.1016/j.jds.2019.01.001. Epub 2019 Apr 02.

BACKGROUND/PURPOSE: Students with different undergraduate trainings may have different responses after taking a combined course with both clinical and basic topics. This study investigated the learning experience of basic science and clinical dentistry by postgraduate students in Institute of...

Cite
Yang H, Chen HY, Lin HY, et al. The learning experience of basic science and clinical dentistry by postgraduate students in Institute of Clinical Dentistry and Institute of Oral Biology. J Dent Sci. 2019;14(3):277-280doi: 10.1016/j.jds.2019.01.001.
Yang, H., Chen, H. Y., Lin, H. Y., & Chen, H. M. (2019). The learning experience of basic science and clinical dentistry by postgraduate students in Institute of Clinical Dentistry and Institute of Oral Biology. Journal of dental sciences, 14(3), 277-280. https://doi.org/10.1016/j.jds.2019.01.001
Yang, Hsiang, et al. "The learning experience of basic science and clinical dentistry by postgraduate students in Institute of Clinical Dentistry and Institute of Oral Biology." Journal of dental sciences vol. 14,3 (2019): 277-280. doi: https://doi.org/10.1016/j.jds.2019.01.001
Yang H, Chen HY, Lin HY, Chen HM. The learning experience of basic science and clinical dentistry by postgraduate students in Institute of Clinical Dentistry and Institute of Oral Biology. J Dent Sci. 2019 Sep;14(3):277-280. doi: 10.1016/j.jds.2019.01.001. Epub 2019 Apr 02. PMID: 31528255; PMCID: PMC6739253.
Copy Download .nbib Format: NLM
HCV infection and the risk of head and neck cancer: A meta-analysis.

Oral oncology

Borsetto D, Fussey J, Fabris L, Bandolin L, Gaudioso P, Phillips V, Polesel J, Boscolo-Rizzo P.
PMID: 32599500
Oral Oncol. 2020 Jun 26;109:104869. doi: 10.1016/j.oraloncology.2020.104869. Epub 2020 Jun 26.

Recent evidence has consistently suggested a role for HCV in the etiology of head and neck squamous cell carcinoma (HNSCC), but the conclusions of these studies have often been limited by small sample size. Therefore, a meta-analysis was performed...

Cite
Borsetto D, Fussey J, Fabris L, et al. HCV infection and the risk of head and neck cancer: A meta-analysis. Oral Oncol. 2020;109:104869doi: 10.1016/j.oraloncology.2020.104869.
Borsetto, D., Fussey, J., Fabris, L., Bandolin, L., Gaudioso, P., Phillips, V., Polesel, J., & Boscolo-Rizzo, P. (2020). HCV infection and the risk of head and neck cancer: A meta-analysis. Oral oncology, 109104869. https://doi.org/10.1016/j.oraloncology.2020.104869
Borsetto, Daniele, et al. "HCV infection and the risk of head and neck cancer: A meta-analysis." Oral oncology vol. 109 (2020): 104869. doi: https://doi.org/10.1016/j.oraloncology.2020.104869
Borsetto D, Fussey J, Fabris L, Bandolin L, Gaudioso P, Phillips V, Polesel J, Boscolo-Rizzo P. HCV infection and the risk of head and neck cancer: A meta-analysis. Oral Oncol. 2020 Jun 26;109:104869. doi: 10.1016/j.oraloncology.2020.104869. Epub 2020 Jun 26. PMID: 32599500.
Copy Download .nbib Format: NLM
Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176].

Oral oncology

Bell RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.
PMID: 28202215
Oral Oncol. 2017 Mar;66:e3. doi: 10.1016/j.oraloncology.2017.02.001. Epub 2017 Feb 12.

No abstract available.

Cite
Bell RB, Gough MJ, Seung SK, et al. Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176]. Oral Oncol. 2017;66:e3doi: 10.1016/j.oraloncology.2017.02.001.
Bell, R. B., Gough, M. J., Seung, S. K., Jutric, Z., Weinberg, A. D., Fox, B. A., Crittenden, M. R., Leidner, R. S., & Curti, B. (2017). Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176]. Oral oncology, 66e3. https://doi.org/10.1016/j.oraloncology.2017.02.001
Bell, R Bryan, et al. "Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176]." Oral oncology vol. 66 (2017): e3. doi: https://doi.org/10.1016/j.oraloncology.2017.02.001
Bell RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B. Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176]. Oral Oncol. 2017 Mar;66:e3. doi: 10.1016/j.oraloncology.2017.02.001. Epub 2017 Feb 12. PMID: 28202215.
Copy Download .nbib Format: NLM
Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41].

Oral oncology

Wang Y, Qin X, Zhu X, Chen W, Zhang J, Chen W.
PMID: 29396179
Oral Oncol. 2018 Mar;78:228. doi: 10.1016/j.oraloncology.2018.01.007. Epub 2018 Feb 01.

No abstract available.

Cite
Wang Y, Qin X, Zhu X, et al. Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41]. Oral Oncol. 2018;78:228doi: 10.1016/j.oraloncology.2018.01.007.
Wang, Y., Qin, X., Zhu, X., Chen, W., Zhang, J., & Chen, W. (2018). Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41]. Oral oncology, 78228. https://doi.org/10.1016/j.oraloncology.2018.01.007
Wang, Yingnan, et al. "Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41]." Oral oncology vol. 78 (2018): 228. doi: https://doi.org/10.1016/j.oraloncology.2018.01.007
Wang Y, Qin X, Zhu X, Chen W, Zhang J, Chen W. Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41]. Oral Oncol. 2018 Mar;78:228. doi: 10.1016/j.oraloncology.2018.01.007. Epub 2018 Feb 01. PMID: 29396179.
Copy Download .nbib Format: NLM
Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use.

Drugs in context

Badowski ME, Burton B, Shaeer KM, Dicristofano J.
PMID: 30815023
Drugs Context. 2019 Feb 13;8:212550. doi: 10.7573/dic.212550. eCollection 2019.

The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for HIV and cancer patients. To address this, current literature and guidelines suggest the continuation of antiretroviral therapy (ART) with oral oncolytic agents to...

Cite
Badowski ME, Burton B, Shaeer KM, et al. Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use. Drugs Context. 2019;8:212550doi: 10.7573/dic.212550.
Badowski, M. E., Burton, B., Shaeer, K. M., & Dicristofano, J. (2019). Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use. Drugs in context, 8212550. https://doi.org/10.7573/dic.212550
Badowski, Melissa E, et al. "Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use." Drugs in context vol. 8 (2019): 212550. doi: https://doi.org/10.7573/dic.212550
Badowski ME, Burton B, Shaeer KM, Dicristofano J. Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use. Drugs Context. 2019 Feb 13;8:212550. doi: 10.7573/dic.212550. eCollection 2019. PMID: 30815023; PMCID: PMC6383448.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 971 entries